EGFR

Summary

Gene Symbol: EGFR
Description: epidermal growth factor receptor
Alias: ERBB, ERBB1, HER1, PIG61, mENA, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, proto-oncogene c-ErbB-1, receptor tyrosine-protein kinase erbB-1
Species: human

Top Publications

  1. ncbi EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
  2. ncbi Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Thomas J Lynch
    Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    N Engl J Med 350:2129-39. 2004
  3. ncbi Screening for epidermal growth factor receptor mutations in lung cancer
    Rafael Rosell
    Catalan Institute of Oncology and Autonomous University of Barcelona, Hospital Germans Trias i Pujol, Barcelona, Spain
    N Engl J Med 361:958-67. 2009
  4. ncbi Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
    Hui-Wen Lo
    Cancer Cell 7:575-89. 2005
  5. ncbi Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1
    G Levkowitz
    Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
    Mol Cell 4:1029-40. 1999
  6. ncbi Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
    Jenn Yu Wu
    Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Clin Cancer Res 14:4877-82. 2008
  7. ncbi Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
  8. ncbi Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation
    Kaisa Haglund
    Ludwig Institute for Cancer Research, Husargatan 3, SE 75 124 Uppsala, Sweden
    Nat Cell Biol 5:461-6. 2003
  9. ncbi Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment
    Natalia Jura
    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA
    Cell 137:1293-307. 2009
  10. ncbi BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    D Li
    Department of Medical Oncology, Dana Farber Cancer Institute, MA, USA
    Oncogene 27:4702-11. 2008

Research Grants

  1. EGFR Mutations in non-Small Cell Lung Cancer
    Bruce Johnson; Fiscal Year: 2009
  2. Molecular Mechanisms of EGF Signaling & Iressa/Tarceva Inhibition in NSCLC
    Karen S Anderson; Fiscal Year: 2010
  3. Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer
    CHAITANYA SURESH NIRODI; Fiscal Year: 2010
  4. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2005
  5. Molecular Mechanisms of EGF Signaling & Iressa/Tarceva Inhibition in NSCLC
    Karen S Anderson; Fiscal Year: 2011
  6. The Odd-Even Effect of Polymorphic CA repeats in the 5' Regulatory Region of the
    IVAN GORLOV; Fiscal Year: 2007
  7. Illuminating Dynamic Receptor Clustering in the Epidermal Growth Factor Receptor
    BJOERN MARKUS REINHARD; Fiscal Year: 2010
  8. Pyrophosphorolysis-activatable helicase dependent amplification assay for lung ca
    BERTRAND LEMIEUX; Fiscal Year: 2007
  9. Targeting Akt/NF-kappa beta for Pancreatic Cancer Therapy
    Fazlul Sarkar; Fiscal Year: 2007
  10. Tyrosine Kinases in Renal Vasoconstrictor Signaling
    PAMELA CARMINES; Fiscal Year: 2007

Detail Information

Publications273 found, 100 shown here

  1. ncbi EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
    ..Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States...
  2. ncbi Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Thomas J Lynch
    Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    N Engl J Med 350:2129-39. 2004
    ..have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response...
  3. ncbi Screening for epidermal growth factor receptor mutations in lung cancer
    Rafael Rosell
    Catalan Institute of Oncology and Autonomous University of Barcelona, Hospital Germans Trias i Pujol, Barcelona, Spain
    N Engl J Med 361:958-67. 2009
    Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer...
  4. ncbi Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
    Hui-Wen Lo
    Cancer Cell 7:575-89. 2005
    Epidermal growth factor receptor (EGFR) exists in the nucleus of highly proliferative cells where it functions as a transcription factor...
  5. ncbi Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1
    G Levkowitz
    Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
    Mol Cell 4:1029-40. 1999
    ..that Cbl adaptor proteins directly control downregulation of the receptor for the epidermal growth factor (EGFR) by recruiting ubiquitin-activating and -conjugating enzymes...
  6. ncbi Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
    Jenn Yu Wu
    Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Clin Cancer Res 14:4877-82. 2008
    ..in patients of non-small cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor (EGFR) are limited...
  7. ncbi Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
    ..predictive of nonresponse and shorter survival in patients treated by anti-epidermal growth factor receptor (anti-EGFR) antibody for metastatic colorectal cancer (mCRC), leading the European Medicine Agency to limit its use to ..
  8. ncbi Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation
    Kaisa Haglund
    Ludwig Institute for Cancer Research, Husargatan 3, SE 75 124 Uppsala, Sweden
    Nat Cell Biol 5:461-6. 2003
    ..Thus, monoubiquitination is the principal signal responsible for the movement of RTKs from the plasma membrane to the lysosome...
  9. ncbi Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment
    Natalia Jura
    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA
    Cell 137:1293-307. 2009
    ..The formation of the activating juxtamembrane latch is prevented by the C-terminal tails in a structure of an inactive kinase domain dimer, suggesting how alternative dimers can prevent ligand-independent activation...
  10. ncbi BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    D Li
    Department of Medical Oncology, Dana Farber Cancer Institute, MA, USA
    Oncogene 27:4702-11. 2008
    Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors...
  11. ncbi Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer
    Sarah Park
    Department of Medicine, Division of Hematology Oncology, Hangang Sacred Heart Hospital, Hallym University School of Medicine, Seoul, Korea
    J Thorac Oncol 4:809-15. 2009
    For the identification of the patients who most likely benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), molecular assays are considered to be of paramount importance...
  12. ncbi Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
    Marc Tischkowitz
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    BMC Cancer 7:134. 2007
    ..The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested.
  13. ncbi Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Alice T Shaw
    Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:4247-53. 2009
    ..To aid in identification and treatment of these patients, we examined the clinical characteristics and treatment outcomes of patients who had NSCLC with and without EML4-ALK...
  14. ncbi Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
    Shiqing Li
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Cell 7:301-11. 2005
    Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unexpected mechanism for ligand-induced receptor dimerization that has important implications for activation and ..
  15. ncbi EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    William Pao
    Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:13306-11. 2004
    Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor...
  16. ncbi Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
    B Corkery
    National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin
    Ann Oncol 20:862-7. 2009
    ..Epidermal growth factor receptor (EGFR) is frequently overexpressed in TNBC...
  17. ncbi Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration
    Takahiro Nakajima
    Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, 1 8 1 Inohana, Chuo Ku, Chiba 260 8670, Japan
    Chest 132:597-602. 2007
    The presence of somatic mutations in epidermal growth factor receptor (EGFR) predicts the effectiveness of EGFR tyrosine kinase inhibitors (TKIs)...
  18. ncbi Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes
    Natalie J Thornburg
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Virol 81:12954-61. 2007
    ..CTAR1 also uniquely upregulates the epidermal growth factor receptor (EGFR). In NPC, NF-kappaB p50/p50 homodimers and the transactivator Bcl-3 were detected on the EGFR promoter...
  19. ncbi A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells
    Miguel A Molina-Vila
    Catalan Institute of Oncology, Medical Oncology Service, Hosptial Germans Trias i Pujol, Badalona, Spain
    J Thorac Oncol 3:1224-35. 2008
    Detection of epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung cancer (NSCLC) patients has relied on DNA purification from biopsies, amplification, and sequencing...
  20. ncbi A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases
    Sara E Monaco
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA
    Hum Pathol 41:94-102. 2010
    Epidermal growth factor receptor (EGFR) and v-Ki-ras 2 (KRAS; viral Kirsten rat sacoma 2 oncogene homolog) oncogenes are predictors of response to EGFR-targeted therapy in lung carcinomas...
  21. ncbi A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling
    Hadassa Waterman
    Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
    EMBO J 21:303-13. 2002
    Ligand-induced desensitization of the epidermal growth factor receptor (EGFR) is controlled by c-Cbl, a ubiquitin ligase that binds multiple signaling proteins, including the Grb2 adaptor...
  22. ncbi Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity
    Giuseppe Viale
    Division of Pathology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:317-28. 2009
    ..significant worse disease-free and overall survival were observed in multivariate analysis, for patients with EGFR immunoreactivity in >or=50% invasive tumor cells (HR 2.39, 95% CI, 1.32-4.34, P = 0.004 for DFS; HR 2.34, 95% CI, 1...
  23. ncbi PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Cancer Res 67:11924-32. 2007
    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective treatments for a subset of non-small cell lung cancers...
  24. ncbi Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
    A Kalikaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece
    Br J Cancer 99:923-9. 2008
    In non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) and K-RAS mutations of the primary tumour are associated with responsiveness and resistance to tyrosine kinase inhibitors (TKIs), respectively...
  25. ncbi Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations
    I Garcia-Olivé
    Servei de Pneumologia, Hospital Germans Trias i Pujol, Carretera de Canyet s n, 08916 Badalona, Spain
    Eur Respir J 35:391-5. 2010
    The presence of somatic mutations of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene in patients with advanced nonsmall cell lung cancer (NSCLC) correlates with a good response to tyrosine kinase inhibitors...
  26. ncbi EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases
    Katharina Schmid
    Clinical Institute of Pathology and Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Clin Cancer Res 15:4554-60. 2009
    The epidermal growth factor receptor (EGFR) and its downstream factors KRAS and BRAF are mutated with different frequencies in non-small cell lung cancer and mutations predict clinical response to EGFR inhibitors...
  27. ncbi A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion
    Pavan Adiseshaiah
    Department of Environmental Health Sciences, Bloomberg School of Public Health, Baltimore, Maryland, USA
    J Cell Physiol 216:405-12. 2008
    ..Furthermore, Fra-1 induced EGFR phosphorylation in an MMP-dependent manner, and an EGFR-specific inhibitor was able to block Fra-1-enhanced cell ..
  28. ncbi Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1
    E Odintsova
    CRC Institute for Cancer Studies, The University of Birmingham, Edgbaston, UK
    Curr Biol 10:1009-12. 2000
    ..We show here that the CD82/KAI-1 tetraspanin is directly associated with the EGF receptor (EGFR), and that ectopic expression of CD82/KAI-1 in epithelial cells specifically suppresses EGF-induced lamellipodial ..
  29. ncbi Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis
    Andrew H A Clayton
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Victoria 3050, Australia
    J Biol Chem 280:30392-9. 2005
    The epidermal growth factor receptor (EGFR) is a member of the erbB tyrosine kinase family of receptors...
  30. ncbi Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion
    Michael P Sanderson
    Tumor Immunology Program, German Cancer Research Center DKFZ, D010 TP3, Im Neuenheimer Feld 580, D 69120 Heidelberg, Germany
    J Cell Biochem 103:1783-97. 2008
    ..In this study, we sought to determine whether ErbB1 receptors are present within exosomes isolated from the human keratinocyte cell line, HaCaT, and whether exosome-..
  31. ncbi PAI-1 mediates the TGF-beta1+EGF-induced "scatter" response in transformed human keratinocytes
    Jennifer Freytag
    Center for Cell Biology and Cancer Research, Albany Medical College, Albany, New York 12208, USA
    J Invest Dermatol 130:2179-90. 2010
    ..Moreover, EGFR signaling blockade or EGFR knockdown attenuated TGF-beta1-induced PAI-1 expression, implicating EGFR ..
  32. ncbi Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor
    Lai Kuan Goh
    Department of Pharmacology, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USA
    J Cell Biol 189:871-83. 2010
    Endocytosis of the epidermal growth factor receptor (EGFR) is important for the regulation of EGFR signaling...
  33. ncbi Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor
    Ole E Sørensen
    Section of Clinical and Experimental Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden
    J Clin Invest 116:1878-85. 2006
    ..These data demonstrate that sterile wounding initiates an innate immune response that increases resistance to overt infection and microbial colonization...
  34. ncbi HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates epidermal growth factor (EGF)-induced degradation of EGF receptor and ACK
    Qiong Lin
    Weis Center for Research, Geisinger Clinic, Danville, Pennsylvania 17822, USA
    Mol Cell Biol 30:1541-54. 2010
    ..an important role in ligand-induced and ubiquitination-mediated degradation of epidermal growth factor receptor (EGFR)...
  35. ncbi Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
    Caterina Peraldo-Neia
    Department of Clinical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy
    BMC Cancer 11:31. 2011
    Activating mutations of the epidermal growth factor receptor (EGFR) confer sensitivity to the tyrosine kinase inhibitors (TKi), gefitinib and erlotinib...
  36. ncbi Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells
    Heather L Watt
    Faculty of Medicine, Department of Experimental Medicine, McGill University, Royal Victoria Hospital, Montreal, QC, Canada
    Cell Signal 21:428-39. 2009
    ..tumour tissues express all five somatostatin receptors (SSTR1-5) and four epidermal growth factor receptors (ErbB1-4)...
  37. ncbi Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop
    Robert Pirker
    Medical University of Vienna, Vienna, Austria
    J Thorac Oncol 5:1706-13. 2010
    Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been characterized in a subset of patients with advanced non-small cell lung cancer (NSCLC)...
  38. ncbi KRAS mutation status in primary nonsmall cell lung cancer and matched metastases
    Alexis B Cortot
    Department of Pulmonary Diseases, Lyon Sud Hospital Center, Claude Bernard University, Lyon, France
    Cancer 116:2682-7. 2010
    ..the mutation status of the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and epidermal growth factor receptor (EGFR) differed between primary tumors and matched distant metastases in nonsmall cell lung cancer (NSCLC).
  39. ncbi Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma
    Jenifer L Marks
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Thorac Oncol 3:111-6. 2008
    Somatic mutations in EGFR (exons 19 and 21) and KRAS (exon 2) are found in lung adenocarcinomas and have potential prognostic value in patients with advanced disease...
  40. ncbi Bile acid regulates MUC2 transcription in colon cancer cells via positive EGFR/PKC/Ras/ERK/CREB, PI3K/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB pathways and negative JNK/c-Jun/AP-1 pathway
    Hwa Young Lee
    Department of Gastroenterology, College of Medicine, Kangnam CHA Hospital, CHA University, Seoul, 650 9, Korea
    Int J Oncol 36:941-53. 2010
    ..constructs and EMSA showed that DCA upregulates MUC2 transcription via multiple pathways involving activation of EGFR/PKC/Ras/Raf-1/MEK1/ERK/CREB, PI3/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB while DCA induced MUC2 transcription is ..
  41. ncbi Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression
    Rafael Rosell
    Catalan Institute of Oncology, Badalona, Spain
    PLoS ONE 4:e5133. 2009
    ..A small fraction of non-squamous cell lung cancers harbor EGFR mutations, with improved outcome to gefitinib and erlotinib...
  42. ncbi The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton
    R B Hazan
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Biol Chem 273:9078-84. 1998
    ....
  43. ncbi Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells
    April Thelemann
    OSI Pharmaceuticals, Inc, Farmingdale, NY 11735, USA
    Mol Cell Proteomics 4:356-76. 2005
    ..Anti-phosphotyrosine and anti-EGFr affinity chromatography, isotope-coded muLC-MS/MS, and immunoblot methods were combined to describe and measure ..
  44. ncbi Epidermal growth factor receptor exposed to cigarette smoke is aberrantly activated and undergoes perinuclear trafficking
    Elaine M Khan
    Signal Transduction Laboratory, Department of Internal Medicine, University of California, School of Medicine, Davis, California, 95616, USA
    FASEB J 22:910-7. 2008
    ..in the gas phase of cigarette smoke (CS), induces aberrant phosphorylation of the epidermal growth factor receptor (EGFR), resulting in the lack of ubiquitination by c-Cbl, and impaired degradation...
  45. ncbi Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus
    Francine Walker
    Department of Pathology, Institut de la Santé et de la Recherche Médicale Unité773, Hopital Bichat Claude Bernard, 75018 Paris, France
    Hum Pathol 40:1517-27. 2009
    ..Human immunodeficiency virus (HIV) promotes anal carcinogenesis. Epidermal growth factor receptor (EGFR), HER2/neu, c-Met, and vascular endothelial growth factor receptor-1 (VEGFR1) (tyrosine kinase growth factor ..
  46. ncbi Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    FEBS J 277:301-8. 2010
    Epidermal growth factor receptor (EGFR) and its three related proteins (the ERBB family) are receptor tyrosine kinases that play essential roles in both normal physiological conditions and cancerous conditions...
  47. ncbi Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting
    John C Sok
    Department of Otolaryngology, and University of Pittsburgh Cancer Institute Biostatistics, University of Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 12:5064-73. 2006
    Epidermal growth factor receptor (EGFR) is overexpressed in head and neck squamous cell carcinoma (HNSCC) where expression levels correlate with decreased survival...
  48. ncbi Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers
    Tatsuya Toyama
    Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho cho, Mizuho ku, Nagoya 467 8601, Japan
    BMC Cancer 8:309. 2008
    ..Triple-negative breast cancer (estrogen receptor-, progesterone receptor-, and HER2-negative) (TNBC) is a high risk breast cancer that lacks specific therapy targeting these proteins...
  49. ncbi Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking
    Elaine M Khan
    Signal Transduction Laboratory, Department of Internal Medicine, University of California, School of Medicine, Davis, California 95616, USA
    J Biol Chem 281:14486-93. 2006
    The epidermal growth factor (EGF) receptor (EGFR) has been found to be overexpressed in several types of cancer cells, and the regulation of its oncogenic potential has been widely studied...
  50. ncbi Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
    Xuewu Zhang
    Department of Molecular and Cell Biology, and Howard Hughes Medical Institute, California Institute for Quantitative Sciences, University of California, Berkeley, California 94720, USA
    Nature 450:741-4. 2007
    Members of the epidermal growth factor receptor family (EGFR/ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4) are key targets for inhibition in cancer therapy...
  51. ncbi Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R
    Bhaumik B Patel
    John D Dingell VA Medical Center, Wayne State University, Detroit, MI 48201, USA
    Int J Cancer 122:267-73. 2008
    ..These changes were associated with decreased expression and activation (tyrosine phosphorylation) of EGFR, HER-2, HER-3 (72-100%) and IGF-1R (67%) as well as their downstream effectors such as Akt and cycloxygenase-2 (51-..
  52. ncbi EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Susumu Kobayashi
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
    N Engl J Med 352:786-92. 2005
    Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors...
  53. ncbi Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain
    Jeffrey C Lee
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 3:e485. 2006
    ..Missense mutations in the EGFR kinase domain, for example, have recently been identified in patients who showed clinical responses to EGFR kinase ..
  54. ncbi Impact of EGFR mutation analysis in non-small cell lung cancer
    Hiromasa Yamamoto
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700 8558, Japan
    Lung Cancer 63:315-21. 2009
    The discovery of mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) accelerated the research of molecular-targeted therapy by EGFR-tyrosine kinase inhibitors (..
  55. ncbi Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation
    Mei Yi Lee
    Institute of Basic Medical Sciences, Department of Obstetrics and Gynecology, National Cheng Kung University, Tainan, Taiwan
    Clin Cancer Res 14:4743-50. 2008
    ..Little is known about the existence and function of EMT in cervical cancer. This study aims to investigate the regulation of EMT in cervical squamous cell carcinoma...
  56. ncbi Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib
    Tona M Gilmer
    Department of Translational Medicine, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    Cancer Res 68:571-9. 2008
    ..effects of non-small cell lung carcinoma (NSCLC)-associated mutations in epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2) on interactions with the dual tyrosine kinase inhibitor lapatinib...
  57. ncbi Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
    Paul H Huang
    Department of Biological Engineering and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 104:12867-72. 2007
    ..EGFRvIII is a truncated extracellular mutant of the EGF receptor (EGFR) commonly found in GBMs that confers enhanced tumorigenic behavior...
  58. ncbi Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy
    Yvonne Hui Fang Teng
    Department of Pathology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore
    Breast Cancer Res 13:R35. 2011
    ..Epidermal growth factor receptor (EGFR) is expressed in triple negative breast cancer and several clinical trials are testing the role of anti-EGFR ..
  59. ncbi A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates
    Olga C J Schuurbiers
    Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Thorac Oncol 5:1664-7. 2010
    Molecular testing for epidermal growth factor receptor (EGFR) and KRAS mutations is of increasing clinical importance in daily practice...
  60. ncbi Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis
    Akihiko Kawahara
    Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan
    Clin Cancer Res 16:3163-70. 2010
    Therapeutic responses of non-small cell lung carcinoma (NSCLC) to epidermal growth factor receptor (EGFR)-targeted drugs, such as gefitinib and erlotinib, are closely associated with activating EGFR mutations...
  61. ncbi Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1
    Marie Josée Demers
    Département d Anatomie et de Biologie Cellulaire, Universite de Sherbrooke, Quebec, Canada
    J Cell Biochem 107:639-54. 2009
    ..IECs, whereas PI3-K/Akt-1 is Src-independent in HCT116, HT29 cells, as in differentiated IECs; and (5) EGFR activity inhibition abrogates anoikis resistance in cancer cells through a loss of Fak-Src interactions and down-..
  62. ncbi Desmoglein 1-dependent suppression of EGFR signaling promotes epidermal differentiation and morphogenesis
    Spiro Getsios
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    J Cell Biol 185:1243-58. 2009
    ..In addition to serving as a rigid anchor between adjacent cells, this study implicates desmosomal cadherins as key components of a signaling axis governing epithelial morphogenesis...
  63. ncbi Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells
    Bahjat Al-Ani
    Department of Reproductive and Vascular Biology, Institute for Biomedical Research, Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Hypertension 55:689-97. 2010
    ....
  64. ncbi Single-molecule diffusion study of activated EGFR implicates its endocytic pathway
    Zeyu Xiao
    Beijing National Laboratory for Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100080, China
    Biochem Biophys Res Commun 369:730-4. 2008
    In this work, we have imaged the lateral diffusion of activated epidermal growth factor receptor (EGFR) on cell membrane for studying its internalization pathway...
  65. ncbi Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer
    C Bengala
    Division of Medical Oncology, Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy
    Ann Oncol 20:469-74. 2009
    ..Gene copy number (GCN) of epidermal growth factor receptor (EGFR) has been suggested to be a predictive factor of response to cetuximab in patients (pts) with mCRC; on the contrary,..
  66. ncbi EGFR and KRAS mutations in patients with adenocarcinoma of the lung
    Tae Won Jang
    Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea
    Korean J Intern Med 24:48-54. 2009
    Mutations of the epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene (KRAS) are important in the pathogenesis of lung cancer, and recent reports have revealed racial and geographical differences in mutation ..
  67. ncbi Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib
    Kazuya Taniguchi
    Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1 3 3 Nakamichi, Higashinari ku, Osaka 537 8511, Japan
    Cancer Sci 99:929-35. 2008
    Somatic mutations introduced into the epidermal growth factor receptor (EGFR) gene in non-small-cell lung cancer (NSCLC) are important factors to determine therapeutic responses to gefitinib...
  68. ncbi Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Dana Farber Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 28:3076-83. 2010
    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations...
  69. ncbi Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor
    Katriina Peltola
    Turku Centre for Biotechnology, University of Turku and Abo Akademi University, Turku, Finland
    Neoplasia 11:629-36. 2009
    ..003). It is also associated to the expression of epidermal growth factor receptor (EGFR, P < .0001), which has been shown to be activated by irradiation...
  70. ncbi Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation
    Nadia Godin-Heymann
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Cancer Res 67:7319-26. 2007
    Activating mutations in the epidermal growth factor receptor (EGFR) characterize a subset of non-small cell lung cancers (NSCLC) with extraordinary sensitivity to targeted tyrosine kinase inhibitors (TKI)...
  71. ncbi Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells
    Dae Hee Lee
    Department of Surgery and Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    J Cell Biochem 106:1113-22. 2009
    ..These results suggest that one of the mechanisms of the apoptotic activity of magnolol involves its effect on epidermal growth factor receptor (EGFR)-mediated signaling transduction pathways.
  72. ncbi The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants
    B M Chung
    Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, 68198 6805, USA
    Oncogene 28:1821-32. 2009
    Non-small cell lung cancer (NSCLC)-associated epidermal growth factor receptor (EGFR) mutants are constitutively active and induce ligand-independent transformation in non-malignant cell lines...
  73. ncbi A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation
    Steven Pennock
    Department of Cell Biology and Signal Transduction Research Group, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada
    Mol Cell Biol 28:3020-37. 2008
    The precise role of Cbl in epidermal growth factor (EGF) receptor (EGFR) endocytosis and trafficking remains to be fully uncovered...
  74. ncbi Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the promotion of cell survival by nerve growth factor
    M Holgado-Madruga
    Department of Microbiology and Immunology, Kimmel Cancer Institute, Thomas Jefferson University, 233 South 10th Street, Bluemle Life Science Building 1002, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 94:12419-24. 1997
    ..Hence, Gab1 has a major role in connecting TrkA with PI 3-kinase activation and for the promotion of cell survival by NGF...
  75. ncbi EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells
    Ming Liu
    Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California 90095, USA
    Am J Respir Cell Mol Biol 37:578-88. 2007
    ..TGF-beta1 and EGF induced COX-2 at the transcriptional and post-transcriptional levels. EGF receptor (EGFR) inhibition, neutralizing antibody against amphiregulin, or mitogen-activated protein kinase kinase (MEK) ..
  76. ncbi Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines
    Jeet Gandhi
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America
    PLoS ONE 4:e4576. 2009
    Deregulation of EGFR signaling is common in non-small cell lung cancers (NSCLC) and this finding led to the development of tyrosine kinase inhibitors (TKIs) that are highly effective in a subset of NSCLC...
  77. ncbi A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor
    Lin Gao
    Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425 2211, USA
    Exp Cell Res 316:376-89. 2010
    ..TK-induced migration was associated with increased phosphorylation of epidermal growth factor receptor (EGFR) and extracellular signal-regulated kinase (ERK), which was blocked by inhibition of protein kinase C (PKC), Src, ..
  78. ncbi RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR
    Michelle Croyle
    Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Cancer Res 68:4183-91. 2008
    ..Based on the observation that the epidermal growth factor receptor (EGFR) kinase inhibitor PKI166 decreased RET/PTC kinase autophosphorylation and activation of downstream effectors in ..
  79. ncbi The membrane-anchoring domain of epidermal growth factor receptor ligands dictates their ability to operate in juxtacrine mode
    Jianying Dong
    Department of Pathology, Division of Cell Biology and Immunology, University of Utah, Salt Lake City, UT 84133, USA
    Mol Biol Cell 16:2984-98. 2005
    All ligands of the epidermal growth factor (EGF) receptor (EGFR) are synthesized as membrane-anchored precursors...
  80. ncbi The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors
    Jin Kyung Rho
    Department of Internal Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
    Mol Cancer Res 7:1736-43. 2009
    The development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) seems almost inevitable, even in patients with lung cancer that initially respond well to EGFR-TKIs...
  81. ncbi Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR
    Zafer Cetin
    Department of Medical Biology and Genetics, Faculty of Medicine, Akdeniz University, Antalya, Turkey
    Med Oncol 27:853-60. 2010
    ..New treatment strategies with EGFR-targeting drugs provided improvements in management of lung cancer...
  82. ncbi Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor
    A G Batzer
    Department of Pharmacology, New York University Medical Center, New York 10016
    Mol Cell Biol 14:5192-201. 1994
    We analyzed the binding site(s) for Grb2 on the epidermal growth factor (EGF) receptor (EGFR), using cell lines overexpressing EGFRs containing various point and deletion mutations in the carboxy-terminal tail...
  83. ncbi HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes
    Benyue Zhang
    Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202 5120, USA
    Oncogene 24:2585-8. 2005
    ..HPV16 E5 enhances the activation of the epidermal growth factor (EGFR)...
  84. ncbi HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells
    Yi Zhang
    Computational Biology and Bioinformatics Group, Pacific Northwest National Laboratory, Richland, WA, 99352, USA
    BMC Cell Biol 10:78. 2009
    ..HME) cells that expresses different levels of HER2 and HER3 receptors in combination with endogenous EGFR/HER1. Using our clone library, we have quantified the receptor activation patterns and systematically tested the ..
  85. ncbi Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH
    Chris Hemmings
    Department of Anatomic Pathology, ACT Pathology at The Canberra Hospital, Canberra, ACT, Australia
    Pathology 41:356-60. 2009
    To assess and compare immunohistochemical expression of epidermal growth factor receptor (EGFR) with gene amplification as demonstrated by chromogenic in situ hybridisation (CISH), in colorectal adenocarcinoma.
  86. ncbi Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications
    Chun Chieh Wu
    Department of Pathology, Chang Gung Memorial Hospital, Tao Yuan, Taiwan
    Cancer 113:3199-208. 2008
    ..cancer (NSCLC), especially in those with adenocarcinoma (30%-50%), but the epidermal growth factor receptor gene (EGFR) mutation rate is very low (3%-8%)...
  87. ncbi First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
    Jenn Yu Wu
    Department of Internal Medicine, National Taiwan University Hospital, No 7 Chung Shan South Road, Taipei 10002, Taiwan
    Am J Respir Crit Care Med 178:847-53. 2008
    ..is effective in treating patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations...
  88. ncbi Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231 1000, USA
    Cancer Res 68:2841-9. 2008
    The epidermal growth factor receptor (EGFR) inhibitor erlotinib is approved for treatment of pancreatic cancer but the overall activity is minimal, and known predictive factors for EGFR inhibitor efficacy are infrequent in this disease...
  89. ncbi Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer
    Koei Ikeda
    Department of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
    Ann Thorac Surg 85:1430-2. 2008
    A novel germline transmission of the epidermal growth factor receptor (EGFR) mutation V843I in a family with multiple members with lung cancer is reported...
  90. ncbi First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
    Akira Inoue
    Tohoku University, Graduate School of Medicine and School of Medicine, Japan
    J Clin Oncol 27:1394-400. 2009
    ..and feasibility of gefitinib for patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations without indication for chemotherapy as a result of poor performance status (PS).
  91. ncbi EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells
    Peter Andersen
    Department of Radiation Biology, The Finsen Center, Copenhagen University Hospital, Copenhagen, Denmark
    Int J Cancer 122:342-9. 2008
    Recently, we reported that epidermal growth factor receptor (EGFR) induce expression of a module of genes known to be inducible by interferons and particularly interferon-gamma...
  92. ncbi Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors
    Justin M Balko
    Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536 0082, USA
    BMC Genomics 7:289. 2006
    ..advanced non-small cell lung cancer (NSCLC) who will benefit from treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI)...
  93. ncbi Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma
    K Kian Ang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:7350-6. 2002
    A correlative study was performed to address the impact of epidermal growth factor receptor (EGFR) overexpression on survival and pattern of failure in patients with advanced head and neck squamous cell carcinomas (HNSCCs) enrolled in a ..
  94. ncbi EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast
    Semir Vranic
    Department of Pathology, Creighton University Medical Center, Omaha, NE 68131, USA
    Mod Pathol 23:644-53. 2010
    This study was undertaken to investigate epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2)/neu expression in a cohort of apocrine carcinomas of the breast with emphasis on the classification of ..
  95. ncbi Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer
    Siu Fun Wong
    Western University College of Pharmacy, Pomona, CA 91766, USA
    Clin Ther 27:684-94. 2005
    Cetuximab is a recombinant human/mouse chimeric epidermal growth factor receptor (EGFR) monoclonal antibody...
  96. ncbi Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells
    Sabina Berezowska
    Division of Neuropathology, Institute of Pathology, Technische Universitat Munchen, D 81675 Munich, Germany
    Int J Mol Med 26:713-21. 2010
    Targeted molecular therapies against the epidermal growth factor receptor (EGFR) are novel, promising and potentially radiosensitising therapeutic approaches in the treatment of glioblastoma, a highly malignant and treatment-refractory ..
  97. ncbi Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein
    Zheng Miao
    Molecular Imaging Program at Stanford, Department of Radiology, Stanford University, Stanford, California 94305 5344, USA
    Bioconjug Chem 21:947-54. 2010
    Epidermal growth factor receptor (EGFR) has become an attractive target for cancer molecular imaging and therapy...
  98. ncbi Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis
    Mathias Munk
    Department of Clinical Biochemistry, Aarhus University Hospital NBG, Aarhus, Denmark
    BJU Int 99:196-201. 2007
    To investigate the effect of the epidermal growth factor receptor (EGFR) on the induction of apoptosis by the chemotherapeutic agent etoposide (VP16), and to examine the effect of combining VP16 with gefitinib to see if the cell-survival ..
  99. ncbi Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib
    Marcus Wiedmann
    Department of Internal Medicine II, University of Leipzig, Leipzig, Germany
    Anticancer Drugs 17:783-95. 2006
    ..b>EGFR was detectable in six of 19 (32%) extrahepatic human cholangiocarcinoma tissue samples, ErbB-2 in 16 of 19 (84%), ..
  100. ncbi Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer
    Yoon Kyung Jeon
    Department of Pathology, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 799, Republic of Korea
    Lung Cancer 54:387-98. 2006
    Increased epidermal growth factor receptor (EGFR) gene copy numbers and mutations predict sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC)...

Research Grants66

  1. EGFR Mutations in non-Small Cell Lung Cancer
    Bruce Johnson; Fiscal Year: 2009
    ..Agents directed against the epidermal growth factor receptor have been developed (EGFR)...
  2. Molecular Mechanisms of EGF Signaling & Iressa/Tarceva Inhibition in NSCLC
    Karen S Anderson; Fiscal Year: 2010
    The epidermal growth factor receptor (EGFR) tyrosine kinase pathway has been demonstrated to be a key molecular target for cancer therapeutics including TKIs such as Iressa (gefinitib) and Tarceva (erlotinib)...
  3. Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer
    CHAITANYA SURESH NIRODI; Fiscal Year: 2010
    ..among these NSCLCs is that they all harbor somatic, activating mutations in the tyrosine kinase domain (TKD) of the EGFR, that have also been linked to tumor sensitivity to small molecule tyrosine kinase inhibitors, gefitinib and ..
  4. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2005
    ..86 percent (43/50) of ErbB-2 positive primary breast tumors were co-expressed with EGFRvIII...
  5. Molecular Mechanisms of EGF Signaling & Iressa/Tarceva Inhibition in NSCLC
    Karen S Anderson; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): The epidermal growth factor receptor (EGFR) tyrosine kinase pathway has been demonstrated to be a key molecular target for cancer therapeutics including TKIs such as Iressa (gefinitib) and Tarceva (..
  6. The Odd-Even Effect of Polymorphic CA repeats in the 5' Regulatory Region of the
    IVAN GORLOV; Fiscal Year: 2007
    ..Epidermal growth factor receptor (EGFR) plays an important role in several processes directly involved in the incidence and progression of breast cancer...
  7. Illuminating Dynamic Receptor Clustering in the Epidermal Growth Factor Receptor
    BJOERN MARKUS REINHARD; Fiscal Year: 2010
    ..Factor Receptor Signal Transduction Pathway Using Plasmon Coupling Aberrant Epidermal Growth Factor Receptor (EGFR) activity has been linked to tumor formation and progression in malignant cells...
  8. Pyrophosphorolysis-activatable helicase dependent amplification assay for lung ca
    BERTRAND LEMIEUX; Fiscal Year: 2007
    ..Cancers over expressing the epidermal growth factor receptor (EGFR) have been shown to increase resistance to chemotherapy, thus increasing the risk of metastases...
  9. Targeting Akt/NF-kappa beta for Pancreatic Cancer Therapy
    Fazlul Sarkar; Fiscal Year: 2007
    ..Over-expression of epidermal growth factor receptor (EGFR) occurs in approximately 90% of human pancreatic cancer...
  10. Tyrosine Kinases in Renal Vasoconstrictor Signaling
    PAMELA CARMINES; Fiscal Year: 2007
    ..effects on vascular smooth muscle through AT1R-dependent transactivation of the epidermal growth factor receptor (EGFR)...
  11. Epidermal Growth Factor Receptor Activation in Pulmonary Fibrosis
    WILLIAM DAVID HARDIE; Fiscal Year: 2010
    ..The epidermal growth factor receptor (EGFR) mediates signals induced by a family of growth factors including transforming growth factor-( (TGF-()...
  12. Drug Resistance in Lung Cancer
    Pasi A Janne; Fiscal Year: 2010
    The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective therapeutic agents for patients with non-small cell lung cancer (NSCLC) whose tumors harbor somatic activating mutations ..
  13. Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer
    KWOK KIN contact WONG; Fiscal Year: 2010
    ..Recently, Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have demonstrated clinical activity in ..
  14. Targeting the HGF/c-Met Pathway in Lung Cancer
    Jill M Siegfried; Fiscal Year: 2010
    ..We also demonstrated the ability of PGE2 to induce release of ligands for the epidermal growth factor receptor (EGFR) and to cause EGFR-dependent phosphorylation of c-Met, which was HGF-independent...
  15. MOLECULAR REGULATION OF CORNEAL WOUND HEALING
    Fu Shin X Yu; Fiscal Year: 2011
    ..The studies in the current grant period demonstrated that epidermal growth factor receptor (EGFR) is the key receptor tyrosine kinase activated upon wounding, and the wound-induced activation of EGFR and its ..
  16. MOLECULAR REGULATION OF CORNEAL WOUND HEALING
    Fu Shin X Yu; Fiscal Year: 2010
    ..The studies in the current grant period demonstrated that epidermal growth factor receptor (EGFR) is the key receptor tyrosine kinase activated upon wounding, and the wound-induced activation of EGFR and its ..
  17. Epidermal Growth Factor Receptor Activation in Pulmonary Fibrosis
    WILLIAM HARDIE; Fiscal Year: 2007
    ..The epidermal growth factor receptor (EGFR) mediates signals induced by a family of growth factors including transforming growth factor-( (TGF-()...
  18. Epidermal Growth Factor Receptor Activation in Pulmonary Fibrosis
    WILLIAM HARDIE; Fiscal Year: 2009
    ..The epidermal growth factor receptor (EGFR) mediates signals induced by a family of growth factors including transforming growth factor-( (TGF-()...
  19. Quantitative Analysis of Epidermal Growth Factor Receptor Signaling Networks
    Forest White; Fiscal Year: 2009
    Overexpression and mutation of epidermal growth factor receptor (EGFR) and EGFR family members leads to dysregulated signal transduction and has been correlated with increased risk for cancer and poor prognosis for cancer patients due ..
  20. The Role of the EGF Receptor in Acute and Chronic Renal Injury
    Raymond Harris; Fiscal Year: 2010
    The Epidermal Growth Factor Receptor (EGFR;HER1) is widely expressed in the kidney, and previous studies have suggested roles for receptor activation in nephrogenesis, regulation of renal physiology and in aberrant growth in renal cell ..
  21. Quantitative Analysis of Epidermal Growth Factor Receptor Signaling Networks
    Forest M White; Fiscal Year: 2010
    Overexpression and mutation of epidermal growth factor receptor (EGFR) and EGFR family members leads to dysregulated signal transduction and has been correlated with increased risk for cancer and poor prognosis for cancer patients due ..
  22. PATTERN FORMATION IN THE DROSOPHILA EYE DISC
    Jessica E Treisman; Fiscal Year: 2010
    ..will investigate several such genes that are required for normal activity of the Epidermal growth factor receptor (EGFR) signaling pathway, which controls the proliferation, survival and differentiation of retinal progenitor cells and ..
  23. Epidermal growth factor receptor signaling in glioma
    Joon Uhm; Fiscal Year: 2006
    Mutations of the gene for epidermal growth factor receptor (EGFR) represent the most common oncogenic alteration in malignant gliomas. While the importance of aberrant EGFR activity in gliomas...
  24. Bile acid-induced colon cancer cell proliferation
    Jean Pierre Raufman; Fiscal Year: 2009
    ..with M3 muscarinic receptors (M3R), thereby causing transactivation of epidermal growth factor receptors (EGFR)...